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Daniel M. Ihnat, MD, Christopher S. Wendel, MS, and Angelika Gruessner, MS, PhD, Tucson, Ariz
Objective: It has been suggested that endovascular aneurysm repair (EVAR) in concert with serial contrast-enhanced
computed tomography (CT) surveillance adversely impacts renal function. Our primary objectives were to assess serial
renal function in patients undergoing EVAR and open repair (OR) and to evaluate the relative effects of method of repair
on renal function.
Methods: A thorough retrospective chart review was performed on 223 consecutive patients (103 EVAR, 120 OR) who
underwent abdominal aortic aneurysm (AAA) repair. Demographics, pertinent risk factors, CT scan number, morbidity,
and mortality were recorded in a database. Baseline, 30- and 90-day, and most recent glomerular filtration rate (GFR)
were calculated. Mean GFR changes and renal function decline (using Chronic Kidney Disease [CKD] staging and
Kaplan-Meier plot) were determined. EVAR and OR patients were compared. CKD prevalence (>stage 3, National
Kidney Foundation) was determined before repair and in longitudinal follow-up. Observed-expected (OE) ratios for
CKDwere calculated for EVAR andOR patients by comparing observed CKD prevalence with the expected, age-adjusted
prevalence.
Results:The only baseline difference between EVAR andOR cohorts was female gender (4% vs 12%, P .029). Thirty-day
GFR was significantly reduced in OR patients (P .047), but it recovered and there were no differences in mean GFR at
a mean follow-up of 23.2 months. However, 18% to 39% of patients in the EVAR and OR groups developed significant
renal function decline over time depending on its definition. OE ratios for CKD prevalence were greater in AAA patients
at baseline (OE 1.28-3.23, depending upon age group). During follow-up, the prevalence and severity of CKD increased
regardless of method of repair (OE 1.8-9.0). Deterioration of renal function was independently associated with age>70
years in all patients (RR 2.92) and performance of EVAR compared with OR (RR 3.5) during long-term follow-up.
Conclusions: Compared with EVAR, OR was associated with a significant but transient fall in GFR at 30 days. Renal
function decline after AAA repair was common, regardless of method, especially in patients >70 years of age. However,
the renal function decline was significantly greater by Kaplan-Meier analysis in EVAR than OR patients during long-term
follow-up. More aggressive strategies to monitor and preserve renal function after AAA repair are warranted. (J Vasc
Surg 2008;47:1141-9.)Since its introduction in 1991, endovascular aneurysm
repair (EVAR) has been well-accepted for patients with
favorable anatomy due to reductions in early morbidity and
mortality compared with open abdominal aortic aneurysm
(AAA) repair.1-3 However, EVAR is associated with unique
and procedure-specific complications such as endoleak,
stent graft migration and collapse, and endograft limb
occlusions. For these reasons, EVAR patients require close
follow-up with serial contrast-enhanced computed tomog-
raphy (CT) surveillance, creating the potential for adverse
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doi:10.1016/j.jvs.2008.01.039effects on renal function due to the endoluminal manipu-
lations and contrast administration required to place the
endograft, as well as the risks of nephrotoxicity from repet-
itive contrast administration associated with serial CT
scans.
The issue of renal function deterioration after EVAR
is important. Numerous authors have analyzed the prob-
lem from a variety of perspectives. Initially, most pub-
lished studies focused on the incidence of early postop-
erative renal insufficiency (30 to 90 days). Existing
reporting standards generally focus on early postopera-
tive renal function decline.4-7 Recently, published inves-
tigations have examined the potential adverse effects of
EVAR on long-term renal function. Progressive renal
function decline is likely to be multifactorial and may be
attributable to pre-existing renal dysfunction, a host of
comorbidities, the AAA repair procedure itself, device-
type, and the diagnostic and therapeutic procedures
required to evaluate and treat endograft-related compli-
cations during follow-up. Pertinent questions, which vari-
ous investigators have sought to answer, generally concern
1141
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insufficiency in AAA patients?8-10; (2) does EVAR adversely
impact renal function compared with open AAA repair (OR),
and if so, how frequently?11-20; (3) among patients undergo-
ing EVAR, is there a difference in the development of renal
function deterioration following infrarenal (IR) vs suprarenal
(SR) fixation?14-16,21-30; (4) do surveillanceCT scans contrib-
ute to renal function deterioration after EVAR?16; (5) what
are the risk factors for declining renal function after EVARand
OR?16,18,19; (6) can EVAR be done safely in patients with
pre-existing renal impairment?11,31-34; and (7) does baseline
renal insufficiency increase perioperative and long-term mor-
bidity and mortality?8
Nearly all published studies of the effect of EVAR on
renal function are limited by short follow-up, lack of open
control groups, variable definitions of postoperative renal
dysfunction, use of serum creatinine level (SCr) instead of
creatinine clearance (CrCl) or glomerular filtration rates
(GFR) as a measure of renal function, and a multitude of
other confounding variables. Some authors have reported
no long-term effect of EVAR on renal function 15,17,21,30
while others have found a significant decline in renal func-
tion over time.3,14,16,22,24,25,29 A recent meta-analysis re-
ported no difference in renal function after EVAR com-
pared with open repair,35 but most studies were short-term
and the definitions of renal function decline were highly
variable. No study has attempted to differentiate expected
serial declines in renal function due to the effects of age and
pre-existing renal function opposed to procedure-related
deterioration.
We were concerned about the potential adverse effect
of serial contrast administration as part of contemporary
EVAR surveillance protocols on renal function. We, there-
fore, analyzed a consecutive series of patients who under-
went EVAR and OR at two affiliated academic institutions
to determine the impact of AAA repair on long-term renal
function.
METHODS
The study was approved by the Institutional Review
Boards of both institutions. Retrospective data were col-
lected on 223 consecutive patients undergoing EVAR and
OR atUniversityMedical Center (UMC) and the Southern
Arizona Veterans Affairs Health Care System (SAVAHCS)
in Tucson, Arizona from January 2001 to December 2006.
Twenty-nine patients undergoing juxtarenal OR were in-
cluded; however, all patients with ruptured aneurysms and
those with preoperative dialysis-dependent renal failure
were excluded. Patient demographics (age, gender, and
weight), comorbidities (coronary disease, hypertension
[HTN], hyperlipidemia, diabetes mellitus, and tobacco
use), maximum aneurysm diameter, follow-up length, ma-
jor morbidity, and mortality were recorded in Microsoft
Excel (Microsoft, Redmond, Wash). In addition, the pres-
ence of renal artery stenosis, use of ACE (angiotensin
converting enzyme) inhibitors and nonsteroidal anti-in-
flammatory drugs (NSAID), and number of contrast stud-ies and total contrast volume were recorded; baseline, 30-
and 90-day, and most recent SCr levels were collected.
Baseline, 30- and 90-day, and most recent glomerular
filtration rate (GFR) were estimated using the Cockcroft-
Gault equation: GFR  (140-age)  weight/72  SCr 
(0.85 if female). The modification of diet in renal disease
(MDRD) study equation was not used since there were very
few African American patients in this series, and the record-
ing of self-identified race was inconsistent and inaccurate.
Changes in mean GFR and chronic kidney disease (CKD)
stage36 as well as the incidence of 10% and 20% post-
operative decline in GFR were calculated for both EVAR
and OR cohorts.
Methodology for analyzing long-term renal func-
tion in study patients. Our primary objective was the
evaluation of long-term rather than acute renal function
decline after AAA repair. There is a published, validated
classification for the evaluation and management of CKD
that has clinical and prognostic significance: the CKD
staging system (NKF/KDOQI -National Kidney Founda-
tion/Kidney Disease Outcomes Quality Initiative).36 This
system was therefore applied in our study.
We stratified baseline renal function as normal (stage 1
and 2: GFR  60 ml/min/1.73m2) and abnormal (CKD
 3, GFR 60). During long-term follow-up, we chose to
define renal function decline differently for each subgroup.
For normal patients, a sustained drop in GFR to 60 (ie,
development of CKD) was defined as renal function de-
cline. Minor GFR fluctuations in patients who remain in
stage 1 or 2 have not been shown to have clinical signifi-
cance. In contrast, for patients whose GFR drops to “60,
the prevalence of complications of CKD increases, as does
the risk of cardiovascular disease.” 36 Therefore, progres-
sion to stage 3 is clinically relevant.
The second issue was how to define renal function
decline in patients with pre-existing CKD at study entry.
CKD stage 3 patients have a 30  GFR  60 ml/min/
1.73m2, stage 4 patients have a GFR  30 ml/min/
1.73m2, and stage 5 patients (excluded from study) are
receiving renal replacement therapy. The natural history of
most forms of CKD tends to be progressive, but the slope
of serial GFR decline is variable. In theMDRD study, mean
GFR decline in CKD patients over 2 years was 4 ml/min/
1.73m2/y and was unrelated to baseline GFR. Rapid de-
cline was defined as a fall in GFR 4/y and slow decline as
4/yr (guidelines 2 and 13).36 Since the majority of study
patients with pre-existing CKD had a baseline GFR in the
range of 40  GFR  59, a 20% reduction in GFR over
2 years would equate to rapid GFR decline (4/y). We
therefore defined renal function decline in CKD patients as
a GFR reduction of 20% (more rapid than expected for
CKD patients as a group) or the need for permanent renal
replacement therapy.
All patients were classified into CKD stages 1 to 4 prior
to intervention. CKD 5 patients undergoing hemodialysis
at the time of AAA repair were excluded. CKD stage was
recalculated for all patients based on GFR at most recent
follow-up visit. Observed CKD stage distribution at base-
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patient age (40 to 59 years, 60 to 69 years, and 70 years)
was compared with the expected distribution of CKD
stages in the general population (NHANES III, Table 26,
guidelines Part IV).36 OE (observed-expected) ratios were
calculated to determine whether clinically significant pro-
gression of CKD occurred after aneurysm repair over time.
OE ratios are an accepted method of evaluating the preva-
lence of given diseases or treatment outcomes in small
populations compared with a large population-based data
base.37
Statistical analysis. Freedom from renal dysfunction
over time was calculated by means of the Kaplan-Meier
method using the definitions of renal function decline
outlined above. We planned to use the log-rank test to
detect differences between the two treatment methods.
Since the two curves cross, the follow-up time was divided
into two periods—short- and long-term follow-up. The
log-rank test was computed separately for the two periods.
These results were confirmed with an extended Cox model
with two heaviside functions. Statistical analyses were per-
formed using SPSS software (SPSS, Inc, Chicago, Ill) with
differences of P  .05 considered statistically significant.
Poisson confidence intervals (CI) for OE ratios were calcu-
lated using a website calculator38 and the CI used was 95%
Poisson exact.
RESULTS
The OR and EVAR groups were comparable (Table I).
Table I. Patient demographics
OR EVAR P value
Age (range) 72.4 (52-86) 73.2 (55-90) .42
Gender (n[%]) .02
Male 105 (88%) 99 (96%)
Female 15 (12%) 4 (4%)
Body weight (kg) 78.7 (49-117) 81.3 (44-144) .56
Risk factors (n[%])
Diabetes mellitus 15 (12.7%) 15 (14.7%) .67
Cardiac disease 51 (43.6%) 46 (15.3%) .89
Hypertension 100 (84.7%) 83 (80.6%) .41
Hyperlipidemia 68 (58.1%) 69 (70.0%) .18
RAS 10 (10.9%) 4 (3.8%) .09
Smokers (active) 47 (39.8%) 27 (28.1%) .20
NSAID 7 (7.1%) 15 (14.6%) .11
ACE inhibitor 29 (29.9%) 42 (41.2%) .10
Aneurysm size
(cmstandard
deviation) 5.9  1.0 5.8  1.1 .09
Number of CT (n
 standard
deviation) 1.4  2.2 5.1  4.1 .001
Length of follow-up
[months
[range]) 20.7 (0-86) 24.7 (0-67) .16
OR,Open abdominal aortic aneurysm repair; EVAR, endovascular abdominal
aortic aneurysm repair; RAS, renal artery stenosis; NSAID, non-steroidal
anti-inflammatory drugs; ACE, angiotensin-converting enzyme; CT, con-
trast computed tomography scan.The distribution of age, weight, and virtually all comorbidi-ties did not differ between study groups. The only signifi-
cant baseline difference was gender with 12% women in the
OR group compared with 4% in the EVAR cohort (P 
.02). The mean number of CT scans also differed signifi-
cantly, 1.4 for OR patients vs 5.1 for EVAR patients (P 
.001), as would be expected for patients undergoing EVAR
surveillance. Mean follow-up was 23.2 months and did not
differ significantly between study groups.
Early postoperative renal dysfunction reflected by a
lower mean GFR at 30-days was more common after OR
than EVAR (P  .047), but this effect was transient and
there was no difference in mean GFR between EVAR and
OR patients at 90 days or anytime thereafter (Table II).
Juxtarenal OR patients had a slightly greater 30-day decline
in GFR than infrarenal OR patients, but this difference was
not statistically significant (P  .11). There was also no
difference between these two OR sub-groups during long-
term follow-up. However, in both OR and EVAR patients,
there was a significant decline in renal function, no matter
how it was defined, in a substantial proportion of patients
during follow-up (Table III). Rates for10% GFR decline
in EVAR and OR patients, respectively, were 38% and 39%;
20% GFR decline 21% and 21%; and 1 CKD stage
increase in 21% and 18.4%. The incidence of renal function
deterioration did not differ between groups when evaluated
by any of these three methods.
CKD staging. The baseline CKD stage distributions
of AAA patients in both EVAR andOR groups by deciles of
age were compared with the expected ratios in a large
population-based study.36 For every age-group except 60
to 69 years, study patients had worse baseline renal function
than the age-adjusted general population, with OE ratios
ranging from 1.17 to 3.8 depending on the subgroup
(Tables IV and V).
We then compared CKD stage distribution at last avail-
able follow-up visit for AAA study patients with the age-
adjusted CKD distribution expected in the general popula-
tion (Tables IV and V). During follow-up, after both OR
and EVAR, OE ratios increased in nearly every age group
and ranged from 1.8 to 9.0, with the most striking increase
in patients 70 years of age.
Freedom from renal dysfunction. Freedom from re-
nal dysfunction for OR and EVAR patients was computed
according to Kaplan-Meier for all patients (Fig, A),
for those with normal baseline renal function (Fig, B), and
for those with preexisting CKD (Fig, C). Since in each
instance the curves cross (30 months for overall analysis, 36
months for patients with normal baseline renal function,
and 24 months for patients with pre-existing CKD), short-
and long-term results were compared.
In all three cases, no short-term differences could be
detected ( P  .38). In contrast, the freedom from renal
dysfunction during long-term follow-up was significantly
higher in OR compared with EVAR patients (P  .03).
Interestingly, the deterioration of renal function could be
shown to occur 12 months earlier in patients with pre-
existing CKD compared with those with normal baseline
renal function.
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(Table VI), which showed a short-term relative risk of
0.920 for EVAR compared with OR (P  .859) and,
therefore, no significant difference in renal dysfunction
between the two methods. In contrast, the hazard ratio for
renal dysfunction for long-term follow-up increased to
3.553 (P  .03) for EVAR and showed a significantly
increased risk of renal dysfunction. In addition, patients
over 70 year of age, independently of the treatment
method, had an increased risk of renal dysfunction (RR 
2.92, P  .01)(Table VI).
DISCUSSION
The main objective of the present study was to deter-
mine if EVAR leads to a greater decline in renal function
over time than would be expected for comparable patients
undergoingOR.We generally obtain routine serial abdom-
inal duplex ultrasound and CT scans at 1 to 3 months, 6
months, and then every 12 months after EVAR; more
frequent scans are obtained if abnormalities of concern
were detected, following re-intervention, and in patients
with clinical signs or symptoms of graft-related problems.
At both UMC and SAVAHCS, CT scans cannot routinely
be obtained in patients with SCr  1.5. In selected cases,
CT scans are obtained in such patients after discussion
between the radiology and vascular surgery attendings and
after arrangements are made to administer N-acetylcysteine
and hydrate the patients before and after contrast adminis-
tration. We anecdotally noted that numerous EVAR pa-
Table II. Mean glomerular filtration rates in open vs endo
term follow-up
Baseline 30-d
OR 70.9  25.4 62.5 
EVAR 71.3  30.7 70.6 
P value 0.91 0.04
EVAR, Endovascular abdominal aortic aneurysm repair; OR, open abdomi
GFR unit mL/min/1.73m2.
Data are reported as mean  standard deviation.
Table III. Long-term decline in glomerular filtration
rates and change in chronic kidney disease (CKD) stage
observed in open and endovascular abdominal aortic
aneurysm repair groups
OR EVAR
10% GFR declinea 46 (38%) 40 (39%)
20% GFR declinea 25 (21%) 22 (21%)
CKD stage declineb 25 (21%) 19 (18.4%)
CKD, Chronic kidney disease; EVAR, endovascular abdominal aortic aneu-
rysm repair; GFR, glomerular filtration rate; OR, open abdominal aortic
aneurysm repair.
aReported as number of patients (percentage) with 10% or 20% GFR decline
compared with baseline GFR.
bCKD change  1 stage.tients during follow-up developed elevated SCr above theradiology department cut-off value (generating numerous
conversations about whether the study should be cancelled,
performed without contrast, or after the above-mentioned
renal protective measures), and wondered whether the
serial decline in renal function in these patients could be
due to repetitive contrast administration. Surowiec et al
recently reported that “a decrease in kidney function is seen
after EVAR . . . . . likely related to the repetitive adminis-
tration of contrast agent.”16
Our review of over 30 reports addressing renal dysfunc-
tion after EVAR1-35 revealed three major problems with
the existing literature: (1) a classification system for baseline
renal dysfunction is lacking; (2) a standard definition of
postoperative renal dysfunction does not exist; and (3) with
rare exceptions, follow-up is short, and data on serial renal
function decline are not presented in Kaplan-Meier format.
Similar to the evaluation of cancer survival or graft
ular repair patients at baseline, 30-day, 90-day, and long-
90-day Last available
63.6  29.4 66.5  30.7
68.2  32.1 65.5  29.0
0.44 0.82
rtic aneurysm repair.
Table IV, A. Comparison of chronic kidney disease
(CKD) stage at baseline and long-term follow-up for all
abdominal aortic aneurysm study patients compared to
chronic kidney disease (CKD) stage distribution expected
for age
Baseline Last follow-up
Expected
for age
Age group 40-59 (n12)
CKD 1 5 (41.7%) 5 (41.7%) 55.7%
2 7 (58.3%) 6 (50.0%) 42.7%
3 0 (0.0%) 1 (8.3%) 1.8%
4 0 (0.0%) 0 (0.0%) —
Age group 60-69 (n56)
CKD 1 22 (38.6%) 20 (37.0%) 38.5%
2 30 (52.6%) 23 (42.6%) 53.8%
3 5 (8.8%) 9 (16.7%) 7.1%
4 0 (0.0%) 2 (3.7%) —
Age group 70 (n154)
CKD 1 15 (9.8%) 14 (9.6%) 25.5%
2 52 (34.0%) 47 (32.2%) 48.5%
3 79 (51.6%) 68 (46.6%) 24.6%
4 7 (4.6%) 16 (11.0%) 1.3%
5 0 (0.0%) 1 (0.7%)
CKD, Chronic kidney disease.
Reported as number (%) of patients.
Expected distribution of chronic kidney disease stages based on data from
the National Health and Nutrition Examination Survey (NHANES III
[1988-1994]). N  15,000, based on one-time assessment of glomerular
filtration rate.36vasc
ay
28.1
31.6
7
nal aopatency, mean percentage survival or patency at a given
hCL 3.85-17.57
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analysis of freedom from renal dysfunction during longi-
tudinal follow-up is required to account for variable
follow-up lengths.
To illustrate the conundrum, our review identified the
following definitions of postoperative renal function de-
cline: SCr levels 1.1, 1.2, 1.3, 1.5, 1.7, 1.8, 2.0, 2.5, and
3.0; SCr rise  1mg/dL above baseline; SCr rise 20%,
30% and 50% above baseline; GFR 45; GFR decline
10%, 20%; and need for hemodialysis. The number of
definitions of renal insufficiency nearly equaled the number
of reports.
The issue of the influence of SR vs IR fixation on renal
function is also unresolved. Surowiec et al compared post-
operative renal function using SCr in 146 EVAR patients,
subgrouping them by IR vs SR fixation, with 65 consecu-
tive OR patients.16 Mean follow-up was 23.2 months. “At
life-table analysis, renal impairment at 36 months was seen
in 36% of patients in the IR group, 25% of patients in the SR
group, and 19% of the OR group (P 0.04 for IR fixation
vs OR).” Macierewicz et al reported the evaluation of 30
EVAR patients with IR (11) and SR (19) fixation studied
by postoperative technetium-labeled diethylene triamine
penta-acetic acid (Tc-DTPA) scans and reported that cov-
erage of renal ostia by bare struts did not effect on renal
function.30 Greenberg et al compared 80 open AAA repair
patients with 190 patients undergoing EVAR with SR
fixation using different definitions of renal dysfunction.15
EVAR patients had less renal dysfunction prior to hospital
discharge than OR patients; subsets of both groups had
renal dysfunction prior to discharge and up to 12 months,
CKD) stage at baseline and at long-term follow up
with CKD stage distribution expected for age
Last follow-up
Expected for ageOR EVAR
1 (20.0%) 4 (57.1%) 55.7%
3 (60.0%) 3 (42.9%) 42.7%
1 (20.0%) 0 (0.0%) 1.8%
0 (0.0%) 0 (0.0%) —
8 (25.8%) 12 (52.2%) 38.5%
15 (48.4%) 8 (34.8%) 53.8%
6 (19.4%) 3 (13.0%) 7.1%
2 (6.4%) 0 (0.0%) —
9 (11.7%) 5 (7.2%) 25.5%
30 (38.9%) 17 (24.6%) 48.5%
29 (37.6%) 39 (56.5%) 24.6%
9 (11.7%) 7 (10.1%) 1.3%
1 (1.4%)
epair; OR, open abdominal aortic aneurysm repair.
he National Health and Nutrition Examination Survey (NHANES III
n rate.36Table V. Prevalence of chronic kidney disease in
abdominal aortic aneurysm study patients at baseline and
in long-term follow-up: observed-expected (OE) ratios
compared with age-matched general population
Observed-expected (OE) ratios
OR
CKD stages 3  4 Baseline Long-term
60-69 y 1.28 (ns) 3.63d
70 y 2.07a 1.9e
 70 y (CKD 4) 3.75b 9.0f
EVAR
CKD stages 3  4
60-69 y 1.17 (ns) 1.84 (ns)
 70 y 2.28c 2.57g
 70 y (CKD 4  5) 3.25 (ns) 8.9h
CKD, Chronic kidney disease; EVAR, endovascular abdominal aortic aneu-
rysm repair; OR, open abdominal aortic aneurysm repair; ns, not significant.
1. Glomerular filtration rate estimated by Cockcroft-Gault equation.
2. CKD defined as glomerular filtration rate 60 ml/min/1.73m2 for 3
months.
3. Expected distribution of chronic kidney disease stages based on data from
the National Health and Nutrition Examination Survey ([NHANES III
[1988-1994]). N  15,000, based on one-time assessment of glomerular
filtration rate.
a-h 95% LCL-UCL (lower confidence level-upper confidence level), Poisson
exact; P  .05
aCL 1.51-2.78
bCL 1.02-9.61
cCL 1.6 -3.02
dCL 1.57-7.16
eCL 1.34-2.62
fCL 4.11-17.07
gCL 1.88-3.43Table IV, B. Comparison of observed chronic kidney disease (
between open and endovascular aneurysm repair study patients
Baseline
OR EVAR
Age group 40-59 (n12)
CKD 1 2 (40.0%) 3 (42.9%)
2 3 (60.0%) 4 (57.1%)
3 0 (0.0%) 0 (0.0%)
4 0 (0.0%) 0 (0.0%)
Age group 60-69 (n56)
CKD 1 11 (33.3%) 11 (45.8%)
2 19 (57.6%) 11 (45.8%)
3 3 (9.1%) 2 (8.3%)
4 0 (0.0%) 0 (0.0%)
Age group 70 (n154)
CKD 1 9 (11.0%) 6 (8.5%)
2 29 (35.4%) 23 (32.4%)
3 40 (48.8%) 39 (54.9%)
4 4 (4.9%) 3 (4.2%)
5
CKD, Chronic kidney disease; EVAR, endovascular abdominal aortic aneurysm r
Reported as number (%) of patients.
Expected distribution of chronic kidney disease stages based on data from t
[1988-1994]). N  15,000, based on one-time assessment of glomerular filtratiobut they reported that this “stabilized or improved at 12 to
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ported that SR is associated with a significantly increased
risk of renal function decline compared with IR or OR
patients.25,26,29
The primary reason for the disparate results reported in
the literature regarding EVAR and long-term renal func-
Fig. Kaplan Meier life-tables: renal function decline, OR vs
EVAR. A, Plot for entire series: renal function decline defined as
progression to chronic kidney disease (CKD) stage 3 or higher for
patients without baseline CKD or 20% glomerular filtration rate
(GFR) decline for patients with pre-existing CKD. B, Renal func-
tion decline after abdominal aortic aneurysm AAA repair for pa-
tients without pre-existing CKD. C, Renal function decline after
AAA repair for patients with pre-existing CKD.tion stems from the lack of standardized definitions. Thewide variability of definitions of renal dysfunction made it
imperative to apply an appropriate renal function classifica-
tion system to allow evaluation of long-term renal function
decline after AAA repair. We believe that long-term assess-
ment of the impact of EVAR, or for that matter, any series
of endovascular diagnostic tests and procedures should be
based on GFR and use CKD staging. The CKD staging
system (NKF/KDOQI -National Kidney Foundation/
Kidney Disease Outcomes Quality Initiative) is the vali-
dated standard for the evaluation and management of
chronic renal disease.36 This staging system was therefore
applied in our study.
This approach leads to the important realizations that
SCr is not reliable in making such determinations and that
CKD prevalence in many subpopulations of patients with
vascular disease, including AAA patients, is higher than
most practitioners realize. For example, the incidence of
CKD in our AAA patients70 years was 56.2%, more than
double that expected in the general population. Even in our
younger AAA patients 40 to 59 years of age (there were
only 12), although there were no CKD patients at baseline,
the proportion of CKD 2:CKD1 patients was reversed
compared with that expected (Table IV, A). Since we
practice at tertiary referral centers, our patients may be
more complex and have a higher incidence of renal insuffi-
ciency than AAA patients seen in community hospitals.
However, the association of AAA and CKD has been
reported by others, and our data appear to confirm it.
Nakamura et al compared baseline renal function in AAA
patients10 to a patient cohort with HTN but without other
risk factors for cardiovascular disease and showed by mul-
tiple methods, including renal scintigraphy, that moderate
or severe renal dysfunction was present in 81% of AAA
patients compared with 58% of HTN patients (P .0001).
Walsh and associates8 identified preoperative renal insuffi-
ciency based on GFR in 33% of preoperative AAA patients.
They also reported that GFR was a much more sensitive
indicator of preoperative CKD than SCr. Using a preoper-
ative SCr of 1.5 identified only 18/52 patients with CKD
(GFR  60 ml/min).
Critics may dispute our use of CKD stages and claim
that it is overly sensitive. Many previous reports have used
SCr, but SCr is influenced by a host of factors other than
GFR including tubular secretion and generation and extra-
renal creatinine excretion. These processes, especially SCr
generation, vary greatly among individuals over time and
Table VI. Relative risk (RR) of factors associated with
renal function decline
Variable Parameter estimate Pr  2
Relative risk
ratio
Age 70 1.07156 0.0104 2.920
Short follow-up* 0.06857 0.8591 0.934
Long follow-up* 1.26217 0.0301 3.533
*EVAR versus ORthe range of SCr levels in normal subjects is wide. SCr is an
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not begin to rise above the upper limits of normal until at
least half of glomerular filtration has been lost.8,36 GFR is
accepted as the best overall index of kidney function in
health and disease; normal GFR varies by age, gender, and
body size. Unlike a rise in SCr, a decrease in GFR precedes
the onset of kidney failure; therefore, a persistently reduced
GFR  60 is a specific indicator of CKD and applies
regardless of age.36
GFR  60 also appears to be associated with increased
perioperative and long-term mortality in aneurysm patients
following EVAR,9 OR,8,39 and thoracoabdominal aneu-
rysm repair.40 No such relationship existed for SCr levels
and survival after aneurysm repair.8,38 GFR measurements,
thus, appear to have clinical and prognostic significance in
AAA patients. Future studies should also examine the in-
fluence of reduced GFR on short- and long-termmorbidity
and mortality; if these impressions are confirmed, determi-
nation of diameter cut-off measurements for intervention
may require adjustment and the decisions for aneurysm
repair in individuals with reduced GFR carefully balanced
against the anticipated risk of rupture. Examination of SCr
alone, as is the usual habit among surgeons, is insensitive in
identifying at-risk patients with CKD.
Early postoperative renal dysfunction was more com-
mon after OR than EVAR but this dysfunction was
transient. This finding has been previously reported and
is likely related to the hemodynamic effects of aortic
cross-clamping, reperfusion injury, blood loss, transient
hypotension, and perioperative fluid shifts.
We identified a significant decline in serial renal func-
tion during follow-up in a substantial proportion of pa-
tients, in line with most previous reports that have analyzed
renal function decline by some arbitrary percentage reduc-
tion in GFR or SCr, with declining function in over 20% to
29% of patients at 2 to 3 years.2,3,14,16,22,24,25 Nonetheless,
unless CKD classification is utilized and CKD deterioration
is compared with age-matched controls, it is difficult to
differentiate any possible detrimental effects of aneurysm
repair on long-term renal function from the natural history
of CKD, which is one of progression. The issue is whether
method of repair accelerates progression and what other
comorbid factors influence renal function decline.
In OR and EVAR patients, we found that increasing
age was strongly associated with renal function decline (RR
2.92 for age  70 years). This finding has not, to our
knowledge, been previously reported. The impact of age
should be examined in larger multicenter studies or registry
databases to determine whether this observation based on
our series is valid and whether age should be considered in
the decision for OR vs EVAR. The situation may prove
analogous to carotid stenting, for which multiple studies
have demonstrated higher stroke risks in octogenarians; age
 80 years is now thought to be a relative contraindication
to carotid stenting.41,42 Our analysis also strongly suggests
that long-term renal function decline is associated with
EVAR compared with OR, even for patients with normal
renal function before intervention.Limitations. The first limitation is the retrospective
and nonrandomized nature of our study. Despite this weak-
ness, OR and EVAR groups were quite similar at baseline
except for gender, likely related to smaller access vessel
diameter or possibly adverse anatomic characteristics of the
aortic neck.
Second, we had 223 patients in our series, which limits
the ability to perform meaningful subgroup analysis and to
identify statistically significant risk factors for progressive
renal function decline (type II error). Nonetheless, except
for meta-analyses, most reports in the literature regarding
post EVAR renal function have had similar numbers of
patients (range 47 to 399), so nearly all published data
suffer from this same limitation.
Third, our method of analysis has not been previously
employed for long-term analysis of renal function in OR or
EVAR patients. We believe our approach is logical, well-
conceived, and evidence-based. SCr is certainly useful in
recognizing major acute changes in renal function in surgi-
cal patients. An accurate estimation of GFR from SCr
requires a steady state of balance (ie, relatively stable SCr
from day to day, which may not be the case in many early
postoperative OR and other surgical patients). SCr can
provide important information about kidney function even
when it is not in a steady state. For example, a daily doubling
of SCr means there is complete shutdown of GFR. Estimated
GFR, in contrast, overestimates true GFR when SCr is rising
and underestimates GFR when SCr is falling (eg, during
recovery phase of acute tubular necrosis).
However, if one wishes to analyze the chronic effects of
endovascular procedures, which involve intraluminal ma-
nipulations in or near the renal arteries, device placement
adjacent to or across the renal ostia and repetitive contrast
administration on renal function, SCr levels are inappropri-
ate and insensitive. Estimated GFR is much more accurate
for assessing longitudinal changes in renal function.
CONCLUSIONS
This study confirms previous observations that the
baseline incidence of CKD is higher in AAA patients than
age-matched controls. We recommend routine measure-
ment of GFR prior to AAA repair because SCr alone,
especially in the elderly, significantly underestimates the
true incidence of CKD. OR transiently worsens renal func-
tion at 30 days, compared with EVAR, but OR patients
recover by 90 days. We were also able to identify a signifi-
cant difference in the incidence of long-term renal function
decline for EVAR compared with OR patients; these differ-
ences were detected after 3 years in patients with normal
baseline renal function and after 2 years in patients with
pre-existing CKD, suggesting that serial contrast adminis-
tration as part of EVAR surveillance was likely a contribut-
ing factor. Compared with expected rates of CKD inci-
dence and severity in the age-matched general population,
renal function significantly worsens after AAA repair by
both OR and EVAR. Age 70 years strongly correlated
with serial renal function decline in all patients. Although
GFR is known to decline with age, “decreased GFR in the
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including not only CKD-related complications, but also
cardiovascular events and mortality.36 We therefore believe
that our use of GFR to assess long-term renal function is
appropriate. In addition, CKD staging has the potential to
be a better method of evaluating chronic changes in renal
function. Therefore, our described method of analysis us-
ing GFR andCKD stage should to be applied in the analysis
of chronic renal function in larger populations of patients
undergoing AAA repair. Unless such a standardized report-
ing methodology is utilized, it will be impossible to accu-
rately determine the effects of different devices, SR vs IR
fixation, repetitive contrast administration and a multitude
of other clinically important issues on long-term renal
function after endovascular therapy. Further study is nec-
essary to determine the frequency with which EVAR pa-
tients require contrast CT scans and which patients are at
greatest risk for CKD decline. Further investigation of
noncontrast CT surveillance combined with duplex imag-
ing and the development of less or nontoxic contrast agents
are also important. Routine hydration and the use of oral
N-acetylcysteine do not appear to provide sufficient protec-
tion from the deleterious effects of repetitive contrast ad-
ministration.
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